• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低 CD8+ 密度变化和 R1 手术切缘是符合米兰标准 HCC 患者术后早期复发的独立预测因素。

Low CD8+ Density Variation and R1 Surgical Margin as Independent Predictors of Early Post-Resection Recurrence in HCC Patients Meeting Milan Criteria.

机构信息

Institute of Biomedical Sciences, Department of Pathology and Forensic Medicine, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania.

National Center of Pathology, Affiliate of Vilnius University Hospital Santaros Clinics, 08406 Vilnius, Lithuania.

出版信息

Curr Oncol. 2024 Sep 10;31(9):5344-5353. doi: 10.3390/curroncol31090394.

DOI:10.3390/curroncol31090394
PMID:39330022
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11431076/
Abstract

Our study included 41 patients fulfilling the Milan criteria preoperatively and aimed to identify individuals at high risk of post-resection HCC relapse, which occurred in 18 out of 41 patients (43.9%), retrospectively. We analyzed whole slide images of CD8 immunohistochemistry with automated segmentation of tissue classes and detection of CD8+ lymphocytes. The image analysis outputs were subsampled using a hexagonal grid-based method to assess spatial distribution of CD8+ lymphocytes with regards to the epithelial edges. The CD8+ lymphocyte density indicators, along with clinical, radiological, post-surgical and pathological variables, were tested to predict HCC relapse. Low standard deviation of CD8+ density along the tumor edge and R1 resection emerged as independent predictors of shorter recurrence-free survival (RFS). In particular, patients presenting with both adverse predictors exhibited 100% risk of relapse within 200 days. Our results highlight the potential utility of integrating CD8+ density variability and surgical margin to identify a high relapse-risk group among Milan criteria-fulfilling HCC patients. Validation in cohorts with core biopsy could provide CD8+ distribution data preoperatively and guide preoperative decisions, potentially prioritizing liver transplantation for patients at risk of incomplete resection (R1) and thereby improving overall treatment outcomes significantly.

摘要

我们的研究纳入了 41 例术前符合米兰标准的患者,旨在确定术后 HCC 复发风险较高的个体,41 例患者中有 18 例(43.9%)发生了 HCC 复发。我们对 CD8 免疫组化的全切片图像进行了分析,采用自动分割组织类别和检测 CD8+淋巴细胞的方法。使用基于六边形网格的方法对图像分析输出进行了抽样,以评估 CD8+淋巴细胞在肿瘤边缘的空间分布。将 CD8+淋巴细胞密度指标与临床、影像学、术后和病理变量进行了测试,以预测 HCC 复发。肿瘤边缘 CD8+密度的标准偏差低和 R1 切除是无复发生存(RFS)较短的独立预测因子。特别是,同时存在这两个不良预测因子的患者在 200 天内复发的风险为 100%。我们的研究结果强调了整合 CD8+密度变异性和手术边界以识别米兰标准满足的 HCC 患者中高复发风险组的潜在效用。在有核心活检的队列中进行验证可以提供术前 CD8+分布数据,并指导术前决策,可能会优先考虑对有不完全切除(R1)风险的患者进行肝移植,从而显著提高整体治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16ac/11431076/65addb09e51c/curroncol-31-00394-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16ac/11431076/2120c3308446/curroncol-31-00394-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16ac/11431076/751d2afcb81a/curroncol-31-00394-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16ac/11431076/65addb09e51c/curroncol-31-00394-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16ac/11431076/2120c3308446/curroncol-31-00394-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16ac/11431076/751d2afcb81a/curroncol-31-00394-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16ac/11431076/65addb09e51c/curroncol-31-00394-g003.jpg

相似文献

1
Low CD8+ Density Variation and R1 Surgical Margin as Independent Predictors of Early Post-Resection Recurrence in HCC Patients Meeting Milan Criteria.低 CD8+ 密度变化和 R1 手术切缘是符合米兰标准 HCC 患者术后早期复发的独立预测因素。
Curr Oncol. 2024 Sep 10;31(9):5344-5353. doi: 10.3390/curroncol31090394.
2
Expansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant platelet-to-lymphocyte ratio.在不做任何牺牲的情况下扩展米兰标准:杭州标准与移植前血小板与淋巴细胞比值的联合应用
BMC Cancer. 2017 Jan 5;17(1):14. doi: 10.1186/s12885-016-3028-0.
3
Preoperative assessment of microvascular invasion risk using gadoxetate-enhanced MRI for predicting outcomes after liver transplantation for single hepatocellular carcinoma within the Milan criteria.使用钆塞酸增强 MRI 对米兰标准内单个肝细胞癌进行术前微血管侵犯风险评估,以预测肝移植术后的结局。
Eur Radiol. 2024 Jan;34(1):498-508. doi: 10.1007/s00330-023-09936-y. Epub 2023 Jul 28.
4
Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.肿瘤内 CD3 和 CD8 T 细胞密度与 HCC 无复发生存相关。
Cancer Immunol Res. 2016 May;4(5):419-30. doi: 10.1158/2326-6066.CIR-15-0110. Epub 2016 Mar 11.
5
Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.射频消融作为潜在可移植患者小于 3cm 的肝细胞癌一线治疗的结果。
J Hepatol. 2019 May;70(5):866-873. doi: 10.1016/j.jhep.2018.12.027. Epub 2019 Jan 5.
6
Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.甲胎蛋白调整至肝癌大小标准与肝癌肝移植后的良好生存相关。
United European Gastroenterol J. 2021 Mar;9(2):209-219. doi: 10.1177/2050640620948665. Epub 2021 Feb 10.
7
Overall Survival Prediction by Tumor Microenvironment Lymphocyte Distribution in Hepatocellular Carcinoma After Liver Transplantation.肝移植后肝细胞癌肿瘤微环境淋巴细胞分布对总生存的预测
J Surg Res. 2024 Mar;295:457-467. doi: 10.1016/j.jss.2023.10.011. Epub 2023 Dec 8.
8
Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria.总体肿瘤负担决定了米兰标准以外的多结节性肝细胞癌患者切除术后的结局。
Ann Surg. 2020 Oct;272(4):574-581. doi: 10.1097/SLA.0000000000004346.
9
Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.同型半胱氨酸:甲胎蛋白阴性肝细胞癌肝移植的新型预后生物标志物。
Cancer Biomark. 2020;29(2):197-206. doi: 10.3233/CBM-201545.
10
Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.影响肝细胞癌肝移植生存因素的研究:来自布达佩斯的单中心经验
Transplant Proc. 2015 Sep;47(7):2201-6. doi: 10.1016/j.transproceed.2015.07.026.

本文引用的文献

1
Changes of long-term survival of resection and liver transplantation in hepatocellular carcinoma throughout the years: A meta-analysis.多年来肝细胞癌切除与肝移植长期生存情况的变化:一项荟萃分析。
Eur J Surg Oncol. 2024 Mar;50(3):107952. doi: 10.1016/j.ejso.2024.107952. Epub 2024 Jan 11.
2
Primary versus Salvage Liver Transplantation after Curative-Intent Resection or Radiofrequency Ablation for Hepatocellular Carcinoma: Long-Term Oncological Outcomes.肝细胞癌根治性切除或射频消融术后原发性肝移植与挽救性肝移植:长期肿瘤学结局
Cancers (Basel). 2023 Oct 18;15(20):5030. doi: 10.3390/cancers15205030.
3
High CD8tumor-infiltrating lymphocytes indicate severe exhaustion and poor prognosis in angioimmunoblastic T-cell lymphoma.
高 CD8+肿瘤浸润淋巴细胞提示血管免疫母细胞性 T 细胞淋巴瘤存在严重衰竭和不良预后。
Front Immunol. 2023 Sep 15;14:1228004. doi: 10.3389/fimmu.2023.1228004. eCollection 2023.
4
Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression.免疫系统与肝细胞癌(HCC):HCC 进展的新见解。
Int J Mol Sci. 2023 Jul 14;24(14):11471. doi: 10.3390/ijms241411471.
5
Comparison of liver resection and living donor liver transplantation in patients with hepatocellular carcinoma within Milan criteria and well-preserved liver function.米兰标准内且肝功能良好的肝细胞癌患者肝切除与活体肝移植的比较
Hepatol Forum. 2023 Mar 27;4(2):47-52. doi: 10.14744/hf.2023.2023.0005. eCollection 2023 Mar.
6
Predictors of early and late hepatocellular carcinoma recurrence.预测早期和晚期肝细胞癌复发的因素。
World J Gastroenterol. 2023 Feb 28;29(8):1243-1260. doi: 10.3748/wjg.v29.i8.1243.
7
Prognostic Value of CD8+ Lymphocytes in Hepatocellular Carcinoma and Perineoplastic Parenchyma Assessed by Interface Density Profiles in Liver Resection Samples.通过肝切除样本的界面密度分布图评估CD8 +淋巴细胞在肝细胞癌及癌旁实质中的预后价值
Cancers (Basel). 2023 Jan 5;15(2):366. doi: 10.3390/cancers15020366.
8
Effect of Tertiary Lymphoid Structures on Prognosis of Patients with Hepatocellular Carcinoma and Preliminary Exploration of Its Formation Mechanism.三级淋巴结构对肝细胞癌患者预后的影响及其形成机制的初步探索
Cancers (Basel). 2022 Oct 21;14(20):5157. doi: 10.3390/cancers14205157.
9
Protective effect of tertiary lymphoid structures against hepatocellular carcinoma: New findings from a genetic perspective.三级淋巴结构对肝细胞癌的保护作用:遗传角度的新发现。
Front Immunol. 2022 Sep 14;13:1007426. doi: 10.3389/fimmu.2022.1007426. eCollection 2022.
10
Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma.肝移植和降期治疗肝细胞癌的十年结果。
JAMA Surg. 2022 Sep 1;157(9):779-788. doi: 10.1001/jamasurg.2022.2800.